Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.34 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL805205 | 0.80 | NCF1 (0.48) | NCF1GNAI3GNAO1GNAI1CACNA2D1 | |
| SCHEMBL10268818 | 0.80 | NCF1 (0.48) | NCF1GNAI3GNAO1GNAI1KEAP1 | |
| SCHEMBL2315572 | 0.79 | EPHX2 (0.44) | EPHX1 | |
| SCHEMBL2419318 | 0.79 | GNAI3 (0.47) | NCF1GNAI3GNAO1GNAI1ACHE | |
| SCHEMBL20312253 | 0.78 | NCF1 (0.46) | NCF1GNAI3GNAO1GNAI1KEAP1 | |
| Hydrochloric Acid SCHEMBL6709111 | 0.78 | NCF1 (0.46) | NCF1GNAI3GNAO1GNAI1 | |
| SCHEMBL11085641 | 0.78 | NCF1 (0.46) | NCF1GNAI3GNAO1GNAI1KEAP1 | |
| SCHEMBL2128921 | 0.78 | NCF1 (0.52) | NCF1GNAI3GNAO1GNAI1KEAP1 | |
| SCHEMBL653829 | 0.78 | — | — | |
| SCHEMBL14947978 | 0.78 | TDP1 (0.35) | EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024506-B2 | Compounds | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-07-02 | — | — | US | disclosed |
| US-12024506-B2 | Compounds | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-07-02 | — | — | US | disclosed |
| EP-3743421-B1 | COMPOUNDS | UNIV OXFORD INNOVATION LTD (GB) | 2023-03-29 | — | — | EP | disclosed |
| US-20210009576-A1 | COMPOUNDS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-01-14 | — | — | US | disclosed |
| EP-3743421-A1 | COMPOUNDS | Oxford University Innovation Limited (GB) | 2020-12-02 | — | — | EP | disclosed |
| US-10669242-B2 | Clostridium difficile toxin inhibitors | Venenum Biodesign, LLC (US) | 2020-06-02 | — | — | US | disclosed |
| EP-3091984-B1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADSTONE (US) | 2020-04-22 | — | — | EP | disclosed |
| EP-3091984-B1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADSTONE (US) | 2020-04-22 | — | — | EP | disclosed |
| US-10611741-B2 | Substituted benzoxazine and related compounds | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2020-04-07 | — | — | US | disclosed |
| US-10611741-B2 | Substituted benzoxazine and related compounds | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2020-04-07 | — | — | US | disclosed |
| US-10087151-B2 | Substituted benzoxazine and related compounds | THE J. DAVID GLADSTONE INSTITUTES, A TESTIMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2018-10-02 | — | — | US | disclosed |
| WO-2017214359-A1 | NOVEL CLOSTRIDIUM DIFFICILE TOXIN INHIBITORS | VENENUM BIODESIGN LLC (US) | 2017-12-14 | — | — | WO | disclosed |
| EP-3091984-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2016-11-16 | — | — | EP | disclosed |
| US-20160326123-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160326123-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160326123-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad (US) | 2016-11-10 | — | — | US | disclosed |
| WO-2015106025-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015106025-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-07-16 | — | — | WO | disclosed |
| US-4424225-A | ANTIULCER AGENTS | DR. KARL THOMAE GMBH (DE) | 1984-01-03 | — | — | US | disclosed |
| EP-0086982-A1 | Substituted thienobenzodiazepinones, process for preparing them and medicines containing them | Dr. Karl Thomae GmbH (DE) | 1983-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009576-A1 | COMPOUNDS | KRAS, NRAS, HRAS | NCF1 558/4885GNAI3 63/4885GNAO1 697/4885 |
| US-20160326123-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | CYP4B1, XDH, UGT2B7 | NCF1 3045/4885GNAI3 2828/4885GNAO1 2615/4885 |
| US-10611741-B2 | Substituted benzoxazine and related compounds | ABCG2, XDH, CYP3A5 | NCF1 1954/4885GNAI3 2582/4885GNAO1 1144/4885 |
| US-10669242-B2 | Clostridium difficile toxin inhibitors | GABRA5, GABRA1, GABBR2 | NCF1 1890/4885GNAI3 2484/4885GNAO1 2823/4885 |
| US-10087151-B2 | Substituted benzoxazine and related compounds | CYP4B1, XDH, UGT2B7 | NCF1 3045/4885GNAI3 2828/4885GNAO1 2615/4885 |
| US-12024506-B2 | Compounds | KRAS, NRAS, HRAS | NCF1 558/4885GNAI3 63/4885GNAO1 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.